Equities research analysts at FinnCap assumed coverage on shares of Abzena PLC (LON:ABZA) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a GBX 100 ($1.24) price target on the stock. FinnCap’s price target would indicate a potential upside of 203.03% from the stock’s previous close.

Separately, N+1 Singer restated a “corporate” rating on shares of Abzena PLC in a research report on Friday, October 21st.

Abzena PLC (LON:ABZA) opened at 33.00 on Thursday. Abzena PLC has a 12-month low of GBX 32.00 and a 12-month high of GBX 66.00. The company’s market cap is GBX 44.94 million. The firm’s 50 day moving average is GBX 39.77 and its 200 day moving average is GBX 43.05.

Abzena PLC Company Profile

Abzena plc is a life sciences company providing services and technologies. The Company is engaged in the provision of services and technology licenses. The Company consists of PolyTherics and Antitope, which have established a suite of services and technologies that are designed to improve the chances of development of antibodies and proteins with therapeutic benefits.

Receive News & Stock Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related stocks with our FREE daily email newsletter.